Cristina Ortega Duran’s Post

ConcertAI became a different organization today with the integration of American Society of Clinical Oncology (ASCO)'s CancerLinQ® program and a long-term agreement with ASCO in real-world data, next-generation quality programs, and digital clinical trials. ConcertAI's definitive RWD will power ASCO-own and aligned research across the research community. ConcertAI trial solutions will power the CancerLinQ TrialLinQ solution in the coming 120 days. There is a deep and multi-year commitment to progressing the automated QOPI® programs of CancerLinQ to advanced and automated ASCO Certified™, the latest quality framework introduced this past July. Many more areas of collaborative innovations to come! #asco #concertai #rwd #rwe #realworldevidence #realworlddata #oncologytrials #oncologytrials https://lnkd.in/eTVFURWW

Momentous day with the announcement of ConcertAI acquisition of ASCO CancerLinQ -- With this integration and this scale, it will be the beginning of more data-driven quality of care programs, more access to health knowledge to power generative and predictive AI for trial participation, regulatory and outcome sciences.

🌟𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐖𝐨𝐫𝐭𝐡 𝟖𝟒𝟖 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐭𝐡𝐞 𝐖𝐨𝐫𝐥𝐝 𝐨𝐟 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 🌐💊 𝐔𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐨𝐟 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲: 🚀 In a groundbreaking move, an Israeli drug developer is set to embark on a transformative journey with a leading American biopharma firm in an exclusive licensing deal valued at an impressive $848 million! Know here more about cancer therapies: https://lnkd.in/dqCFzvWZ 🔬 Compugen, leveraging its computational prowess, delves into vast datasets to pinpoint compounds with the potential to revolutionize immunotherapy. Their latest gem, #COM503, takes center stage by disrupting the interaction between the protein IL-18 and Interleukin-18, a crucial cytokine governing immune and blood cell activities. 🛑 Why is this crucial? IL-18's delicate balance ensures a controlled immune response, preventing autoimmune diseases like Crohn’s and rheumatoid arthritis. COM503 strategically intervenes, allowing Interleukin-18 to thwart tumor growth in cancer patients. 🤝 Under the new agreement, Compugen spearheads ongoing preclinical development and the future Phase 1 study of COM503. Following this, the reins pass to the esteemed Gilead Sciences, granting them exclusive rights for further development and commercialization. 💰 The deal unfolds with an upfront payment of $60 million, followed by an additional $30 million upon FDA clearance for clinical trials. But that's not all—Compugen stands to receive up to a staggering $758 million in future development and commercial milestones, along with enticing royalties on sales. 🌐 Join us on this riveting expedition as we reshape the landscape of cancer treatment. Together, we're not just advancing science; we're paving the way for a future where innovation meets impact. 💡🌍 #BiopharmaInnovation #CancerResearch #ImmunotherapyRevolution #CollaborationForACure

If managed right, this could revolutionize the way data can be used to design trials, to represent marginalized groups, and to set a course to clinical practice oriented solutions. Excellent acquisition! Whomever thought of this…. not sure if you realize yet how much it could change everything! Not an easy road ahead in cleaning and properly curating the data—but if you can simultaneously develop your own research cooperative group and root it in training and education at the GME, community practice, and academic center level…it’s the future of oncology! Well done and God speed ConcertAI! American Society of Clinical Oncology (ASCO) AI in Precision Oncology #clinicaltrials #cancer #innovation

𝐆𝐢𝐥𝐞𝐚𝐝 𝐚𝐧𝐝 𝐀𝐫𝐜𝐮𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐀𝐦𝐞𝐧𝐝𝐞𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐄𝐪𝐮𝐢𝐭𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 Gilead Sciences Gilead Sciences and Arcus Biosciences Arcus Biosciences announce a collaboration agreement amendment and a $320 million equity investment by Gilead in Arcus at $21.00 per share. This accelerates joint development programs spanning multiple indications. 👥 Johanna Mercier Johanna Mercier, Chief Commercial Officer at Gilead, joins Arcus Board, enhancing collaboration governance for streamlined decision-making. 💡 Focus on advancing Phase 3 studies STAR-121 (lung cancer) and STAR-221 (gastrointestinal cancer) for the domvanalimab program, aiming for full enrollment by year-end. Plans include initiating STAR-131, a new Phase 3 lung cancer study. 🔍 Reprioritization reflects commitment to the TIGIT pathway and the Fc-silent design of domvanalimab, offering potential differentiation in efficacy and safety. 📈 Investment extends Arcus's cash runway into 2027, supporting Phase 3 studies in pancreatic and kidney cancer. 🛑 Discontinuation of Phase 3 ARC-10 study to prioritize STAR-121 and STAR-221. Grateful to patients and investigators in ARC-10; data and insights will be shared. ⚠️ No observed changes to domvanalimab and zimberelimab safety and efficacy profiles. #agreement #collaboration #safety #healthcare #clinicaltrials #Oncology #MedicalAdvancements #TIGITPathway #Phase3Studies

The PRIME-ROSE vision aims to make Precision Cancer Medicine (PCM) accessible and affordable to all cancer patients. To achieve this goal, we are collaborating and sharing data from our trials across Europe. Please read more from the latest PRIME-ROSE news splash https://lnkd.in/e5bfhFzH #HorizonEurope #PrecisionMedicine #DRUPtrials #PRIMEROSE_EU #ClinicalTrials #RareCancer #precisiononcology #datasharing

Our MEDSIR team is presenting #LUPER trial and two substudies from #PHERGainTrial. We look forward to meeting you! If you're attending #ESMO23 too, let's chat and explore synergies for strategic #clinicalresearch! #oncology  #innovation  #bringyourideatolife

Only 3 days left until the start of #ESMO23 Congress, the most significant European event in the field of oncology, which we, as a company committed to the discovery of innovative treatments in this area, will be attending! Within the framework of this year's event, the most influential doctors, researchers, and representatives of the healthcare industry in the sector will be sharing the latest cutting-edge data. In this regard, we will have the opportunity to present the results of three of our studies: LUPER, focusing on small-cell #LungCancer; and two translational substudies from #PHERGainTrial for HER2+ early #BreastCancer, centered around analyzing Trop-2 expression and the other aiming to further validate the HER2DX® tool. Learn more about this event organized by the ESMO - European Society for Medical Oncology here: https://lnkd.in/dBWNycCF See you soon! https://lnkd.in/dG3kHYS5 #MEDSIR #Bringyourideatolife #clinicaltrials #cancerresearch

🌟 AstraZeneca Shines at ASCO24: Leading the Charge in Oncology Innovation🌟 At Lampgen Clinical Research, we recognize the paramount importance of having expert oncology CRAs to ensure cancer clinical trials meet ICH/GCP and industry standards. As the staffing firm of choice for sponsors and CROs, we pride ourselves on supporting groundbreaking research like AstraZeneca's recent successes at ASCO24. AstraZeneca continues to impress, with its sixth consecutive year of plenary presentations, showcasing two promising studies. The results from Tagrisso and Imfinzi are particularly noteworthy, offering significant advancements in lung cancer treatment. These achievements highlight AstraZeneca's commitment to pushing the boundaries of cancer research, a commitment we share at Lampgen. The road to success in oncology is fraught with challenges, but with the right team and strategic innovation, breakthroughs are possible. AstraZeneca's optimism and strategic partnerships, including with Chinese firm AbelZeta Pharma, exemplify the potential of global collaboration in accelerating cancer treatment development. At Lampgen, we are dedicated to providing the skilled professionals necessary to monitor these vital trials, ensuring data integrity and patient safety. Together, we can make strides in the fight against cancer. 🔬💼 #OncologyResearch #ClinicalTrials #CancerResearch #CRAs #LampgenClinicalResearch #ASCO24 #AstraZeneca #Tagrisso #Imfinzi #InnovativeMedicine #GlobalHealth #PharmaIndustry #ClinicalExcellence #PatientCare 🔗 https://lnkd.in/eWquSfnU

Clinical pathways have become a critical decision-support tool to help standardize evidence-based care and manage rising cancer care cost. In a recent article for Fierce Biotech, I explored the key implications, challenges, and opportunities for biopharma companies in the evolving clinical pathways landscape. Check out the full article below. https://lnkd.in/gPvC2RnS